Seres Therapeutics, Inc.

This company is a clinical-stage firm dedicated to enhancing patient outcomes in medically vulnerable groups by discovering and developing new live biotherapeutic product (LBP) candidates. The company successfully developed and secured approval for VOWST, the first FDA-approved orally administered microbiome biotherapeutic and a Breakthrough Therapy designated drug, which was sold to Société des Produits Nestlé S.A. (SPN) and its affiliates, collectively Nestlé Health Science, in September 2024. The company possesses advanced capabilities and platforms, supported by human data sets, to progress a portfolio of products that address diseases by targeting host pathways modulated by microbes in the human body, particularly those associated with mucosal barrier-immune interface targets. Clinical and nonclinical data from its programs support the development of LBPs to prevent and treat a wide range of infections, and to treat inflammatory and immune (I&I) diseases. Its pipeline includes SER-155, SER-603, and SER-147, along with other potential candidates in earlier development. The LBP candidates are bacterial consortia designed for specific pharmacological properties and oral delivery. The company maintains a distinct live biotherapeutics drug discovery and development platform, including good manufacturing practices (GMP) manufacturing capabilities. Pipeline assets, such as SER-155 and SER-603, are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation. The company's knowledge and platforms enable precise consortia design to achieve specific clinical outcomes and offer insights into microbe-associated disease targets. It designs LBP candidates to modulate host function, aiming to increase epithelium integrity, induce immune homeostasis and tolerance, and prevent pathogen colonization and overgrowth in the gastrointestinal (GI) tract.